BusinessGeneral NewsHealthcareIndustry

Pharmacogenetic Testing Market Competitive Intelligence Insights 2019 – 2026: Sonic Healthcare; Genelex; GENEWIZ; Rxight; 23andMe

Pharmacogenetic Testing Market

Pharmacogenetic testing is a diagnostic procedure used for the determination of drug and an individual’s genetic make-up interaction. This test is experiencing high demand as various scientists and researchers have identified the unique reactions between each individuals’ genes and drugs which has resulted in the development of a unique test which can record this interaction and provide valuable insights which is subsequently used for the development of personalized therapeutics.

The Major players profiled in this report include Sonic Healthcare; Genelex; GENEWIZ; Rxight; 23andMe, Inc.; PGXT; OneOme, LLC; Mako Medical Laboratories, LLC; Myriad Genetics, Inc.; Bayer AG; BGI; Pacific Biosciences of California, Inc.; F. Hoffmann-La Roche Ltd; QIAGEN; Luminex Corporation; Eurofins Scientific; Illumina, Inc.; Thermo Fisher Scientific Inc.; PerkinElmer Inc. among others.

Have Queries? To request a sample or speak to an expert click here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenetic-testing-market

Let’s know why the report is worth considering-

Utilizes Powerful Tools and Methodologies-: The Pharmacogenetic Testing market has been evaluated and analyzed utilizing various powerful market research tool and methodologies such as SWOT analysis, income feasibility analysis, PEST analysis and PORTER’s Five Forces analysis. These tools analyze the competitive forces prevailing in the market which somehow affects the market growth.

Competitive Rivalry-:The Pharmacogenetic Testing report incorporates the detailed analysis of the leading organizations and their thought process and what are the methodologies they are adopting to maintain their brand image in this market. The report aides the new bees to understand the level of competition that they need to fight for to strengthen their roots in this competitive market.

Highlights following MARKET DRIVERS AND RESTRAINT:

  • Favorable scenario of reimbursement for these tests from the insurance providers is expected to propel the growth of the market
  • Increasing demand for personalized therapeutic system and diagnostic tests is expected to drive the growth of the market
  • Lack of skilled individuals that can conduct and provide valuable insights from the test results is expected to act as a restraint for the growth of the market
  • Large levels of financial costs associated with these tests is expected to restrict the growth of the market

To get this report at an attractive cost, click here: https://databridgemarketresearch.com/request-a-discount/global-pharmacogenetic-testing-market

Conducts Overall PHARMACOGENETIC TESTING Market Segmentation: This knowledgeable market research report offers lucrative opportunities by breaking down complex market data into segments on the basis of –

  • By Type (Single Gene Tests, Array-Based Tests, Whole Genome Sequencing & NGS, Whole Exome Sequencing),
  • Sample (Blood, Saliva),
  • Therapeutic Area (Oncology, Neurology, Cardiology, Genomics, Immunology & Hypersensitivity, Others),
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies, Direct-To-Customer Services)

The PHARMACOGENETIC TESTING report covers market shares for global, Europe, North America, Asia Pacific and South America. The analysis of this report has been used to examine various segments that are relied upon to witness the quickest development based on the estimated forecast frame.

Key Developments in the Market:

In January 2019, 23andMe, Inc. announced the availability of pharmacogenomics test which will be commercially available without the need for any prescriptions. This test will help provide patients and physicians with better knowledge and identification services into genes of an individual. Although, FDA has approved this test they have also issued a statement regarding not basing their treatment options on the test results

In May 2017, Oxford Gene Technology announced that had agreed to be acquired by Sysmex Corporation. This acquisition will allow for complete integration of Oxford’s genetic analysis technologies and expertise which will help enhance the position of Sysmex Corporation globally. Oxford Gene Technology will operate as a wholly-owned subsidiary of Sysmex

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

There are 13 Chapters to thoroughly display the Pharmacogenetic Testing market.

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 Pharmacogenetic Testing market Size by Regions

6 Sales Channel, Distributors, Traders and Dealers

7 North America Pharmacogenetic Testing Revenue by Countries

8 Europe Pharmacogenetic Testing Revenue by Countries

9 Asia-Pacific Pharmacogenetic Testing Revenue by Countries

10 South America Pharmacogenetic Testing Revenue by Countries

11 Middle East and Africa Revenue Pharmacogenetic Testing by Countries

12 International Players Profiles

13 Market Forecast 2019-2026

14 Analyst’s Viewpoints/Conclusions

15 Appendix

Read Complete Details with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenetic-testing-market                   

For any special requirements in this report, please contact us to order a report tailored to fit your requirements.

Report Rating
Close